+38 044 223 28 95
00380930552240 (باللغة العربية)
+38 044 223 28 95
Request Info

News and articles on arthritis

Newts shed light on possible ways of stem cell treatment for osteoarthritis 22 August 2015

The scientists from the Arthritis Research UK Tissue Engineering Centre at the University of York department of biology have found way to rejuvenate cells taken from older osteoarthritis patients in order to repair their worn or damaged cartilage.

Stem Cell Therapy Will Be Tested For Rheumatoid Arthritis Patients 20 November 2014

Stem cells derived from fat tissue will be used in clinical trials for treating rheumatoid arthritis patients starting 2015.

Mesenchymal Stem Cells Prove Effective in Animal Trials for Rheumatoid Arthritis Treatment 26 August 2012

Animal trials of Mesoblast\'s mesenchymal stem cells in rheumatoid arthritis (RA) have encouraged the company press on with an FDA application for a phase II trial.

Research Supports Using Fat Stem Cells to Treat Rheumatoid Arthritis 07 March 2012

A Panamanian-led, multidisciplinary research team has published the first description of non-expanded fat stem cells in the treatment of rheumatoid arthritis patients.

All news

Rheumatoid Arthritis

Transplantation of fetal stem cells allows for achieving conspicuous positive results in treatment of rheumatoid arthritis. Indications for transplantation of fetal stem cells in patients with rheumatoid arthritis are as follows:
  • rheumatoid arthritis resistant to standard treatment;
  • ineffective anti-inflammatory drug therapy, including glucocorticoids and cytostatics;
  • marked decrease in functional capacity of joints;
  • trophic disturbances of the musculoskeletal system (complications of rheumatoid arthritis);
  • considerable deviations of immunologic and hemopoetic parameters.
For treating patients with seropositive, seronegative rheumatoid arthritis of activity grades I–III, with joint functional insufficiency of grades I–III, fetal stem cells of mesodermal, ectodermal, and endodermal origin are used.

As early as within the first days after transplantation, the early post-transplantation improvement syndrome is observed in all patients: diminishing weakness, increased motion activity, normalization of sleep, improved appetite.

Within three months after transplantation, inflammatory process activity decreases: morning stiffness, joint tenderness and oedema diminish, Ritchie’s index decreases, patients’ functional capacity improves; ESR decreases or returns to normal; C-reactive protein levels and rheumatoid factor titer decline; CD3+, CD8+, and NK lymphocyte count is restored.

In most cases (85%), complete discontinuation or considerable dose reduction of glucocorticoids and non-steroidal inflammatory drugs (NSAIDs) had been achieved. According to X-ray data, no progression of joint damage is observed in 72% of patients.

In 80% patients it was possible to achieve remission along with better quality of life. Remission lasted from six months to three years. Experience shows that clinical remission starts well before improvement of laboratory parameters. In case of unfavourable clinical course of rheumatoid arthritis, repeated transplantations of fetal stem cells are carried out.

Duration of rheumatoid arthritis treatment course at Cell Therapy Center EmCell, as a rule, totals 2 days.
Fetal Stem Cells in Osteoarthrosis (poster presentation). English, jpg, 2 Mb

Use of Fetal Stem Cells in Treatment of Patients with Rheumatoid Arthritis (poster presentation).
English, pdf, 1.5 Mb

Request additional information